These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

595 related articles for article (PubMed ID: 31653147)

  • 21. Clinical significance of promoter hypermethylation of DNA repair genes in tumor and serum DNA in invasive ductal breast carcinoma patients.
    Sharma G; Mirza S; Parshad R; Srivastava A; Gupta SD; Pandya P; Ralhan R
    Life Sci; 2010 Jul; 87(3-4):83-91. PubMed ID: 20470789
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Tumor cell-specific BRCA1 and RASSF1A hypermethylation in serum, plasma, and peritoneal fluid from ovarian cancer patients.
    Ibanez de Caceres I; Battagli C; Esteller M; Herman JG; Dulaimi E; Edelson MI; Bergman C; Ehya H; Eisenberg BL; Cairns P
    Cancer Res; 2004 Sep; 64(18):6476-81. PubMed ID: 15374957
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Aberrant methylation of RASSF2A in tumors and plasma of patients with epithelial ovarian cancer.
    Wu Y; Zhang X; Lin L; Ma XP; Ma YC; Liu PS
    Asian Pac J Cancer Prev; 2014; 15(3):1171-6. PubMed ID: 24606436
    [TBL] [Abstract][Full Text] [Related]  

  • 24. BRCA1 promoter hypermethylation on circulating tumor DNA correlates with improved survival of patients with ovarian cancer.
    Elazezy M; Prieske K; Kluwe L; Oliveira-Ferrer L; Peine S; Müller V; Woelber L; Schmalfeldt B; Pantel K; Joosse SA
    Mol Oncol; 2021 Dec; 15(12):3615-3625. PubMed ID: 34601813
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Epigenetic inactivation of BRCA1 through promoter hypermethylation in ovarian cancer progression.
    Wang YQ; Yan Q; Zhang JR; Li SD; Yang YX; Wan XP
    J Obstet Gynaecol Res; 2013 Feb; 39(2):549-54. PubMed ID: 23006047
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Ras association domain family protein 1a hypermethylation and PD-L1 expression in ovarian cancer: A retrospective study of 112 cases.
    Zhu X; Yang H; Lang J; Zhang Y
    Eur J Obstet Gynecol Reprod Biol; 2019 Sep; 240():103-108. PubMed ID: 31242460
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Methylation Status and Expression of BRCA2 in Epithelial Ovarian Cancers in Indonesia.
    Pradjatmo H
    Asian Pac J Cancer Prev; 2015; 16(18):8599-604. PubMed ID: 26745123
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Lost expression of DCC gene in ovarian cancer and its inhibition in ovarian cancer cells.
    Meimei L; Peiling L; Baoxin L; Changmin L; Rujin Z; Chunjie H
    Med Oncol; 2011 Mar; 28(1):282-9. PubMed ID: 20054719
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Germline Mutations of BRCA1 and BRCA2 in Korean Ovarian Cancer Patients: Finding Founder Mutations.
    Choi MC; Heo JH; Jang JH; Jung SG; Park H; Joo WD; Lee C; Lee JH; Lee JM; Hwang YY; Kim SJ
    Int J Gynecol Cancer; 2015 Oct; 25(8):1386-91. PubMed ID: 26402875
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Hypermethylation of the RASSF1A tumor suppressor gene in Japanese clear cell renal cell carcinoma.
    Tokinaga K; Okuda H; Nomura A; Ashida S; Furihata M; Shuin T
    Oncol Rep; 2004 Oct; 12(4):805-10. PubMed ID: 15375503
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Recurrent BRCA1 Mutation, but no BRCA2 Mutation, in Vietnamese Patients with Ovarian Carcinoma Detected with Next Generation Sequencing.
    Vu HA; Phu ND; Khuong LT; Hoa PH; Nhu BTH; Nhan VT; Thanh LQ; Sinh ND; Chi HT; Quan ND; Binh NT
    Asian Pac J Cancer Prev; 2020 Aug; 21(8):2331-2335. PubMed ID: 32856862
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Development and validation of a microRNA-based signature (MiROvaR) to predict early relapse or progression of epithelial ovarian cancer: a cohort study.
    Bagnoli M; Canevari S; Califano D; Losito S; Maio MD; Raspagliesi F; Carcangiu ML; Toffoli G; Cecchin E; Sorio R; Canzonieri V; Russo D; Scognamiglio G; Chiappetta G; Baldassarre G; Lorusso D; Scambia G; Zannoni GF; Savarese A; Carosi M; Scollo P; Breda E; Murgia V; Perrone F; Pignata S; De Cecco L; Mezzanzanica D;
    Lancet Oncol; 2016 Aug; 17(8):1137-1146. PubMed ID: 27402147
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Gross genomic alterations and gene expression profiles of high- grade serous carcinoma of the ovary with and without BRCA1 inactivation.
    Pradhan M; Risberg BA; Tropé CG; van de Rijn M; Gilks CB; Lee CH
    BMC Cancer; 2010 Sep; 10():493. PubMed ID: 20843305
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Association of folate and other one-carbon related nutrients with hypermethylation status and expression of RARB, BRCA1, and RASSF1A genes in breast cancer patients.
    Pirouzpanah S; Taleban FA; Mehdipour P; Atri M
    J Mol Med (Berl); 2015 Aug; 93(8):917-34. PubMed ID: 25805039
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Promoter Hypermethylation and Expression Changes of BRCA1 Gene in a Cohort of Sporadic Breast Cancer Cases among Pakistani Population.
    Arif T; Anwar N
    Asian Pac J Cancer Prev; 2020 Aug; 21(8):2395-2401. PubMed ID: 32856871
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Methylation Profiles of BRCA1, RASSF1A and GSTP1 in Vietnamese Women with Breast Cancer.
    Vu TL; Nguyen TT; Doan VTH; Vo LTT
    Asian Pac J Cancer Prev; 2018 Jul; 19(7):1887-1893. PubMed ID: 30049201
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Clinicopathologic characteristics and survival in BRCA1- and BRCA2-related adnexal cancer: are they different?
    Reitsma W; de Bock GH; Oosterwijk JC; ten Hoor KA; Hollema H; Mourits MJ
    Int J Gynecol Cancer; 2012 May; 22(4):579-85. PubMed ID: 22274543
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Aberrant promoter methylation of the RASSF1A and APC genes in epithelial ovarian carcinoma development.
    Bhagat R; Chadaga S; Premalata CS; Ramesh G; Ramesh C; Pallavi VR; Krishnamoorthy L
    Cell Oncol (Dordr); 2012 Dec; 35(6):473-9. PubMed ID: 23055343
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Imprinted tumor suppressor genes ARHI and PEG3 are the most frequently down-regulated in human ovarian cancers by loss of heterozygosity and promoter methylation.
    Feng W; Marquez RT; Lu Z; Liu J; Lu KH; Issa JP; Fishman DM; Yu Y; Bast RC
    Cancer; 2008 Apr; 112(7):1489-502. PubMed ID: 18286529
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Correlation of preoperative ROMA scores with clinical stage in epithelial ovarian cancer patients.
    Li QL; Wang CJ; Qi P; Zhang YX
    Clin Transl Oncol; 2017 Oct; 19(10):1260-1267. PubMed ID: 28444641
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 30.